Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer Post author: Post published: January 27, 2024 Post category:uncategorized Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. You Might Also Like 2024 CSCO Breast Cancer guidelines revolutionize treatment approaches in China February 14, 2025 Researchers urge caution over large-scale newborn genome screening June 15, 2026 Low income linked to higher risk of dying from liver cancer May 5, 2025